Boobalan Pachaiyappan
Stock Analyst at Roth MKM
(3.87)
# 632
Out of 4,818 analysts
10
Total ratings
40%
Success rate
18.62%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Boobalan Pachaiyappan
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRVO CervoMed | Maintains: Buy | $15 → $20 | $8.84 | +126.24% | 3 | Mar 18, 2025 | |
| VRNA Verona Pharma | Initiates: Buy | $68 | $64.75 | +5.02% | 1 | Jan 10, 2025 | |
| CING Cingulate | Initiates: Buy | $12 | $4.35 | +175.86% | 1 | Jan 10, 2025 | |
| RVPH Reviva Pharmaceuticals Holdings | Initiates: Buy | $7 | $0.89 | +685.28% | 1 | Jan 10, 2025 | |
| GANX Gain Therapeutics | Maintains: Buy | $7 | $1.88 | +272.34% | 2 | Dec 24, 2024 | |
| TRDA Entrada Therapeutics | Initiates: Buy | $29 | $8.98 | +222.94% | 1 | Dec 5, 2024 | |
| LGVN Longeveron | Initiates: Buy | $10 | $1.63 | +513.50% | 1 | Dec 5, 2024 |
CervoMed
Mar 18, 2025
Maintains: Buy
Price Target: $15 → $20
Current: $8.84
Upside: +126.24%
Verona Pharma
Jan 10, 2025
Initiates: Buy
Price Target: $68
Current: $64.75
Upside: +5.02%
Cingulate
Jan 10, 2025
Initiates: Buy
Price Target: $12
Current: $4.35
Upside: +175.86%
Reviva Pharmaceuticals Holdings
Jan 10, 2025
Initiates: Buy
Price Target: $7
Current: $0.89
Upside: +685.28%
Gain Therapeutics
Dec 24, 2024
Maintains: Buy
Price Target: $7
Current: $1.88
Upside: +272.34%
Entrada Therapeutics
Dec 5, 2024
Initiates: Buy
Price Target: $29
Current: $8.98
Upside: +222.94%
Longeveron
Dec 5, 2024
Initiates: Buy
Price Target: $10
Current: $1.63
Upside: +513.50%